AAAAAA
Results:
1-8
|
Results: 8
Authors:
Beltrame, D
di Salle, E
Giavini, E
Gunnarsson, K
Brughera, M
Citation: D. Beltrame et al., Reproductive toxicity of exemestane, an antitumoral aromatase inactivator,in rats and rabbits, REPROD TOX, 15(2), 2001, pp. 195-213
Authors:
Makridakis, NM
di Salle, E
Reichardt, JKV
Citation: Nm. Makridakis et al., Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II, PHARMACOGEN, 10(5), 2000, pp. 407-413
Authors:
Kvinnsland, S
Anker, G
Dirix, LY
Bonneterre, J
Prove, AM
Wilking, N
Lobelle, JP
Mariani, O
di Salle, E
Polli, A
Massimini, G
Citation: S. Kvinnsland et al., High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment, EUR J CANC, 36(8), 2000, pp. 976-982
Authors:
Kaufmann, M
Bajetta, E
Dirix, LY
Fein, LE
Jones, SE
Zilembo, N
Dugardyn, JC
Nasurdi, C
Mennel, RG
Cervek, J
Fowst, C
Polli, A
di Salle, E
Arkhipov, A
Piscitelli, G
Miller, LL
Massimini, G
Citation: M. Kaufmann et al., Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial, J CL ONCOL, 18(7), 2000, pp. 1399-1411
Authors:
Lonning, PE
Bajetta, E
Murray, R
Tubiana-Hulin, M
Eisenberg, PD
Mickiewicz, E
Celio, L
Pitt, P
Mita, M
Aaronson, NK
Fowst, C
Arkhipov, A
di Salle, E
Polli, A
Massimini, G
Citation: Pe. Lonning et al., Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial, J CL ONCOL, 18(11), 2000, pp. 2234-2244
Authors:
Zaccheo, T
Giudici, D
Panzeri, A
di Salle, E
Citation: T. Zaccheo et al., Combined treatment of Dunning R3327 rat prostatic tumor with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide, CANC CHEMOT, 45(1), 2000, pp. 31-37
Authors:
Zaccheo, T
Giudici, D
di Salle, E
Citation: T. Zaccheo et al., Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and theantiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats, ENDOCR-R CA, 6(3), 1999, pp. 429-435
Authors:
Jones, S
Vogel, C
Arkhipov, A
Fehrenbacher, L
Eisenberg, P
Cooper, B
Honig, S
Polli, A
Whaley, F
di Salle, E
Tiffany, J
Consonni, A
Miller, L
Citation: S. Jones et al., Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer, J CL ONCOL, 17(11), 1999, pp. 3418-3425
Risultati:
1-8
|